RPL12P50

Across TCGA pan-cancer cohorts, RPL12P50 RNA differs between tumor and matched normal tissue in 5 of 18 cancer types tested, making tumor–normal expression one of RPL12P50’s most consistent transcriptional readouts.

The strongest signal is observed in stomach adenocarcinoma (STAD), where RPL12P50 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types RPL12P50 is over-expressed in tumor, although a few such as LIHC show the opposite, repressed pattern.

STAD, COAD, and PRAD are the cancer types where RPL12P50 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in RPL12P50 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
STAD	All	All	+0.728	.004	5	view →
COAD	All	II,III,IV	+0.258	.029	4	view →
PRAD	All	All	+0.139	.001	2	view →
LUAD	All	II,III,IV	+0.170	.024	1	view →
LIHC	Female	All	−0.081	.037	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 5 strongest of 5 lineages.

RPL12P50–STAD

Open the STAD breakdown →